SHEET 1 OF 1

4	1	N.
•	4) .

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

	SHEET _L_ OF _I
ATTORNEY'S DKT No.	APPLICATION NO.
033136-119	09/541,033
APPLICANT	
Richard G. Miller	
FILING DATE	GROUP
March 31 2000	1644

ER		U.	S. PATENT DOCUMENTS					
	U.S. Patent Document		Name of Patentee or Applicant of Cited Document					
Examiner Initials	Number (if known)				Date of Publication (MM-DD-YYYY)			
			EIGN PATENT DOCUMENT	S				
	Foreign Pater							
Examiner Initials	Number	Kind Code (if known)	Country		Date of Publication (MM-DD-YYYY)		Translation Yes no	
		NON PAT	ENT LITERATURE DOCUM	FNTS			L	
Examiner Initials	item (bool	e name of author (in k, magazine, journal, pu	CAPITAL LETTERS), title of the a serial, symposium, catalog, etc.), blisher, city and/or country where	rticle (when date, page published.	(s), volume-issue num	ber(s),		
avr	January 15, 1997,	y News, Companies , Vol. 17, No. 2., pag	Take Broad Range of Approache	s to Develo	p Rheumatoid Arthritis	Therapi	es,	
3WL	Chen, Y.L., et al., Pharmacol., Decen	"Anti-tumor necrosis nber 27, 1994, 271:(factor properties of non-peptide (2-3), pp. 319-327. Absteact	drugs in acu	ite-phase responses,"	Eur. J.		
				,				
Examiner Signature	I how		Date Considered	2/19/	62			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.